Upregulated expression of PD‐L1 is a common feature of tumour cells to avoid immune‐mediated destruction and blocking PD‐L1 or its receptor PD‐1 with antagonistic monoclonal antibodies is a well‐recognized approach to boost the anti‐tumour immune response in many different cancer types.42, 43, 44. This evidence concerns the gene CD274 and cancer.